Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-8-11
pubmed:abstractText
A beta-lactamase-stable antibiotic, the oral penem FCE 22891 (ritipenem acoxil), was investigated for use in exacerbations of chronic obstructive pulmonary disease (COPD). Thirteen of the 15 COPD patients had a proven lower respiratory tract infection. Symptom scores and forced expiratory volumes in 1 s significantly improved during therapy with FCE 22891 in combination with bronchodilators and intravenous corticosteroids. Conversion of representative sputum to nonrepresentative sputum or eradication of the original pathogen in representative sputum was effected in 12 patients. Resistance to FCE 22891 was observed in three cases with Haemophilus influenzae. Gastrointestinal disturbances, of which one was severe, were experienced by eight patients. Although FCE 22891 has some beneficial effect in exacerbations of COPD, there are reservations about its use because of adverse effects and potential inefficacy in the treatment of infection with H. influenzae.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-1416398, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-14268279, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2086216, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2111092, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2127342, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2203300, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2732139, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2786517, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2786518, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-2997100, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-3038012, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-3122301, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-3132370, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-3378958, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-5763088, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-6309725, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-6607032, http://linkedlifedata.com/resource/pubmed/commentcorrection/8031062-6616097
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
872-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Clinical and bacteriological efficacy and tolerability of FCE 22891 in patients with exacerbations of chronic obstructive pulmonary disease.
pubmed:affiliation
Department of Pulmonary Diseases, University Hospital Groningen, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't